Cargando…
Can NLRP3 inhibitors improve on dexamethasone for the treatment of COVID-19?
Dexamethasone, a corticosteroid, has been approved for use in the treatment of severe COVID-19, which is characterised by hyperinflammation and associated lung damage. However, dexamethasone shows no clinical benefit in the treatment of less severe disease, and prolonged treatment may lead to immuno...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390447/ https://www.ncbi.nlm.nih.gov/pubmed/34870152 http://dx.doi.org/10.1016/j.crphar.2021.100048 |